Daily Sepsis Research Analysis
Analyzed 31 papers and selected 3 impactful papers.
Summary
Three mechanistic studies advance sepsis biology: ER stress amplifies hyperinflammation via IκBζ–XBP1s cooperation coupled to Regnase-1 degradation, a cell-intrinsic immunometabolic defect suppresses NK-cell IFN-γ responses and associates with nosocomial infections, and ZBP1-driven macrophage pyroptosis drives epithelial mitochondrial dysfunction in sepsis-induced lung injury. Together, they nominate tractable targets (IκBζ/XBP1s axis, AMPK–mTORC1 tuning, ZBP1) for future precision interventions.
Research Themes
- ER stress–immune signaling cross-talk driving hyperinflammation
- Immunometabolic dysfunction of NK cells and secondary infection risk
- ZBP1-mediated macrophage pyroptosis impairing alveolar epithelial integrity
Selected Articles
1. ER stress amplifies inflammation via a dual mechanism involving IκBζ-XBP1s synergism and Regnase-1 degradation.
ER stress augments inflammation through two coordinated layers: it stabilizes Nfkbiz mRNA by promoting IKK-dependent Regnase-1 degradation and drives selective secondary-response gene transcription via IκBζ–XBP1s synergism. This axis was required for excessive IL-6 production in septic mice, nominating IκBζ accumulation as a therapeutic target in ER stress-associated hyperinflammation.
Impact: It delineates a previously unrecognized dual mechanism linking ER stress to hyperinflammation and demonstrates in vivo relevance for IL-6 overproduction during sepsis.
Clinical Implications: Targeting IκBζ accumulation, preserving Regnase-1 function, or disrupting IκBζ–XBP1s cooperativity may attenuate IL-6–driven immunopathology in sepsis and other ER stress–linked inflammatory disorders. Translation will require target-selective modulators and biomarker-guided patient selection.
Key Findings
- ER stress synergizes with TLR signaling to markedly upregulate IκBζ in macrophages.
- Calcium-dependent, IKK-mediated degradation of Regnase-1 stabilizes Nfkbiz mRNA, promoting IκBζ accumulation.
- IκBζ cooperates with XBP1s to drive transcription of selective secondary-response genes (e.g., Il6, Nos2).
- The IκBζ–XBP1s synergy is required for excessive IL-6 production in septic mice.
Methodological Strengths
- Integrated in vitro macrophage models with in vivo septic mouse validation.
- Mechanistic dissection spanning transcriptional synergy and post-transcriptional mRNA stabilization.
Limitations
- Human clinical validation and pharmacologic target modulation were not reported.
- Gene-specific amplification was highlighted; broader transcriptomic specificity and potential off-target effects remain to be mapped.
Future Directions: Develop small-molecule or genetic modulators of IκBζ/XBP1s interaction and Regnase-1 stability; validate pathway activity and predictive biomarkers in human sepsis cohorts; assess therapeutic index in preclinical infection models.
Inflammatory diseases arise from complex interactions between immune signaling and cellular stress. Although endoplasmic reticulum (ER) stress is a key modulator of immunity, the mechanisms by which it promotes inflammatory pathology remain incompletely understood. Notably, ER stress-induced NF-κB activation alone is insufficient to account for robust IL-6 production, thus suggesting the involvement of additional regulators. Using bone marrow-derived macrophages and sepsis model mice, we identified the inducible transcription factor IκBζ as a critical mediator of this response, with ER stress synergizing with TLR signaling to markedly upregulate IκBζ. Mechanistically, ER stress triggered calcium-dependent signaling that led to IκB kinase-mediated degradation of the RNase Regnase-1, likely stabilizing Nfkbiz mRNA and promoting the accumulation of IκBζ, which was found to cooperate with the ER stress factor XBP1s to drive transcription of selected secondary-response genes, particularly Il6 and Nos2. Importantly, this synergy was required for excessive IL-6 production in septic mice, highlighting a gene-specific amplification pathway. Together, these findings identify a dual mechanism in which transcriptional synergy between IκBζ and XBP1s is coupled to posttranscriptional mRNA stabilization via Regnase-1 degradation, thereby linking proteotoxic stress to hyperinflammatory responses. Our results establish ER stress-mediated IκBζ accumulation as a key driver of inflammatory pathogenesis and a potential therapeutic target in ER stress-associated inflammatory disorders.
2. Disturbed metabolic adaptation drives natural killer cell dysfunction in association with nosocomial infection during human sepsis.
In sepsis, circulating NK cells exhibit a cell-intrinsic defect characterized by reduced IL-12 receptor expression, impaired mTORC1 activation, diminished nutrient transporter expression, and blunted IFN-γ responses for at least 14 days. Ex vivo AMPK inhibition restored mTORC1 signaling and IFN-γ production, linking immunometabolic dysregulation to secondary infection susceptibility.
Impact: This human longitudinal study defines a reversible immunometabolic lesion in NK cells associated with nosocomial infections, highlighting AMPK–mTORC1 as a therapeutic axis.
Clinical Implications: Monitoring NK-cell metabolic fitness and IL-12 responsiveness may identify patients at risk for secondary infections; immunometabolic interventions (e.g., AMPK modulation) warrant controlled trials to restore NK competence in sepsis.
Key Findings
- NK cells from septic patients show reduced IL-12 receptor expression and impaired IFN-γ responses for at least 14 days, especially in those who develop secondary infections.
- Defects are cell-intrinsic and associated with impaired mTORC1 activation and reduced nutrient transporter expression.
- Ex vivo AMPK inhibition restores mTORC1 signaling and increases IFN-γ production in NK cells from septic patients.
Methodological Strengths
- Longitudinal human sampling linking immune function to clinical phenotype (secondary infections).
- Mechanistic rescue experiments demonstrating reversibility via AMPK inhibition.
Limitations
- Exploratory study with unspecified sample size and without interventional clinical outcomes.
- Ex vivo pharmacologic modulation may not fully recapitulate in vivo safety and efficacy.
Future Directions: Quantify effect sizes in larger cohorts, develop metabolic biomarkers of NK competence, and test immunometabolic therapies (e.g., AMPK–mTORC1 modulation) in early-phase clinical trials to reduce nosocomial infections.
BACKGROUND: Patients with sepsis are highly susceptible to detrimental nosocomial infections. During bacterial infection, natural killer (NK) cells release Interferon (IFN) γ that drives the elimination of invading pathogens. Interleukin (IL) 12 in synergy with other cytokines increases sensing and uptake of nutrients by NK cells for metabolic adaptation required for induction of IFN-γ production. We hypothesised that inappropriate function of NK cells was associated with nosocomial infections during human sepsis and linked to altered metabolic adaptation. METHODS: We performed a longitudinal exploratory study on circulating human NK cells during sepsis and evaluated adaptation of nutrient sensing, activation of the metabolic hub mammalian target of rapamycin (mTOR) C1, and IFN-γ production upon exposure to Staphylococcus aureus as a model for an opportunistic pathogen in vitro. The involvement of cell-intrinsic and extrinsic pathways in NK cell function was addressed. FINDINGS: Expression of the IL-12 receptor (p < 0.001) and downstream production of IFN-γ (p < 0.01) after exposure to S. aureus were suppressed in NK cells for at least 14 days after sepsis diagnosis, particularly in patients who developed secondary infections (p < 0.01). Mechanistically, suppression of NK cells was independent from environmental cues but was cell-intrinsic and associated with impaired activation of mTORC1 and with reduced expression of nutrient transporters required for anabolic metabolism. Inhibition of AMP kinase (AMPK) restored mTORC1 activity (p < 0.01) and increased the production of IFN-γ (p < 0.01) in NK cells from septic patients. INTERPRETATION: Defective metabolic regulation is associated with persistent NK cell dysfunction during human sepsis and might represent a potential therapeutic target to improve immune competence and decrease the risk for nosocomial infections. FUNDING: The study was supported by the "Research and Training" program "ELAN" for medical students of the medical faculty of the University Duisburg-Essen.
3. ZBP1-driven pyroptosis-associated alveolar macrophages exacerbate epithelial dysfunction in sepsis.
Integrated single-cell analyses from human BALF and septic mouse lungs reveal an expanded macrophage subset with ZBP1-dependent inflammasome activation and pyroptosis that impairs AT2 epithelial mitochondrial function and barrier integrity. Genetic loss of Zbp1 attenuates macrophage–epithelial inflammatory crosstalk, nominating ZBP1 as a target to mitigate sepsis-induced ALI.
Impact: It mechanistically links ZBP1-driven macrophage pyroptosis to epithelial mitochondrial dysfunction in sepsis-induced ALI using human and murine single-cell datasets with genetic validation.
Clinical Implications: ZBP1 inhibition or modulation of macrophage pyroptosis may protect alveolar barrier integrity and reduce organ failure in sepsis-associated lung injury; biomarker development for ZBP1 activity could guide patient selection.
Key Findings
- A distinct subset of pyroptosis-associated alveolar macrophages expands in sepsis-induced ALI and exhibits ZBP1-dependent inflammasome activation.
- ZBP1 activation promotes macrophage pyroptosis and releases mediators that impair AT2 epithelial mitochondrial function and barrier integrity.
- Zbp1 deficiency diminishes macrophage–epithelial inflammatory signaling and mitigates epithelial injury in vivo.
Methodological Strengths
- Cross-species single-cell RNA-seq integration linking human disease with mechanistic mouse models.
- Genetic validation via Zbp1 deficiency to establish causality in vivo.
Limitations
- Sample sizes and patient heterogeneity are not detailed in the abstract, limiting generalizability assessment.
- Therapeutic ZBP1 inhibition was not tested in clinical settings; safety profile remains unknown.
Future Directions: Quantify ZBP1 activity as a biomarker in sepsis ALI cohorts, develop selective ZBP1 inhibitors, and evaluate efficacy/safety in preclinical infection models prior to early-phase trials.
The lung is highly vulnerable to inflammatory injury during sepsis, and acute lung injury (ALI) is a major cause of mortality in critically ill patients. Pyroptosis amplifies immune responses by promoting the release of inflammatory cytokines, and Z-DNA binding protein 1 (ZBP1) has emerged as a key upstream regulator of programmed cell death and inflammatory signaling. Nevertheless, the contribution of ZBP1 to human sepsis-induced ALI and its associated cellular programs remains poorly defined. Here, by integrating single-cell RNA sequencing data from bronchoalveolar lavage fluid (BALF) of patients with sepsis-induced ALI and from septic mouse lungs, we identified a distinct subset of pyroptosis-associated macrophages that expands during disease progression and exhibits ZBP1-dependent inflammasome activation. ZBP1 activation promoted inflammasome assembly, induced macrophage pyroptosis, and released pro-inflammatory mediators that impaired mitochondrial function and barrier integrity of alveolar type II (AT2) epithelial cells. ZBP1 deficiency markedly attenuated macrophage-AT2 inflammatory signaling and reduced the inflammatory amplification loop. Collectively, these findings identify ZBP1-mediated macrophage pyroptosis as a critical mechanism driving epithelial dysfunction during sepsis-induced ALI and provide a rationale for developing ZBP1-targeted strategies to restore immune-epithelial homeostasis and prevent organ failure in sepsis.In sepsis-induced acute lung injury, ZBP1 drives macrophage pyroptosis and amplifies inflammatory signaling, thereby promoting mitochondrial dysfunction, inflammatory activation, and barrier integrity loss in AT2 epithelial cells. Zbp1 deficiency suppresses macrophage pyroptosis, weakens macrophage-epithelial inflammatory crosstalk, and mitigates epithelial injury.